Archives
-
Y-27632 for ROCK Signaling and Organoids
2026-09-30
Y-27632 enables reversible ROCK1 and ROCK2 inhibition for connecting cytoskeletal dynamics modulation with patient-derived organoid workflows. Use it to separate dissociation-related recovery effects from tissue-processing variables in colorectal cancer models, while retaining clear dose and vehicle controls.
-
Preserving Phosphorylation in Ferroptosis
2026-09-30
New evidence positions mitochondrial permeability transition pore opening, oxidized mitochondrial DNA release, and cGAS–STING signaling as an integrated ferroptosis axis. This thought-leadership guide explains how rigorous protein phosphorylation preservation with Phosphatase Inhibitor Cocktail 3 can strengthen translational interpretation without confusing sample-protection tools with mechanistic proof.
-
Protease Inhibitor Cocktail for PTM Fidelity
2026-09-29
Discover how a Protease Inhibitor Cocktail protects protein abundance and preserves interpretation of phosphorylation, ubiquitination, and interaction assays. This guide connects EDTA-free extraction strategy with mechanistic insights from plant immunity research.
-
OSMI-1: Decoding OGT Control of Trophoblast Stress
2026-09-29
OSMI-1 is a cell-permeable O-GlcNAc transferase inhibitor for dissecting how protein O-GlcNAc modification influences trophoblast ferroptosis. This article presents a perturbation-aware framework that separates OGT target engagement, iron-dependent stress, syncytialization defects, and compound-associated cytotoxicity.
-
Trelagliptin Succinate and Adipocyte Insulin Resistance
2026-09-28
The reference study examines how trelagliptin succinate may improve insulin resistance in differentiated 3T3-L1 adipocytes beyond its established DPP-4 inhibitory activity. Its central finding is that trelagliptin strengthens the IRS-1/PI-3K/AKT/GLUT4 axis while reducing free fatty acid and resistin secretion, connecting intracellular insulin signaling with adipocyte metabolic output.
-
Okadaic acid: PP1/PP2A Workflow Guidance
2026-09-28
Okadaic acid (A4540) supports controlled investigation of phosphorylation-dependent signaling by inhibiting PP2A at lower concentrations and PP1 at higher concentrations. It is suited to validated biochemical and cell-based studies, including apoptosis assays, but its biochemical IC50 values should not be treated as cellular dosing instructions or evidence of pathway specificity.
-
Y-27632 in Medulloblastoma Organoid Research
2026-09-27
Y-27632 is a selective ROCK inhibitor that can help researchers investigate how cytoskeletal state shapes measurements in patient-derived medulloblastoma organoids. This article connects ROCK biology with a recent organoid study while distinguishing established findings from proposed experimental applications.
-
Phosphatase Inhibitor Cocktail 2 for Liver Signaling
2026-09-26
Phosphatase Inhibitor Cocktail 2 can help preserve stress-responsive phosphorylation during liver sample preparation. This article connects the 2024 CerS6–mitochondria study to practical assay decisions, clarifying what phosphatase inhibition protects—and what it cannot prove.
-
Lambda Protein Phosphatase for BMAL1 Studies
2026-09-25
Use Lambda Protein Phosphatase to test whether BMAL1 phosphorylation contributes to condensate formation and circadian transcription. This practical workflow pairs broad dephosphorylation with matched controls, phospho-antibody checks, and phase-separation readouts—while distinguishing global phosphorylation effects from site-specific conclusions.
-
A Brain-to-Spinal Circuit for Opioid Mechanical Pain
2026-09-25
Yin and colleagues identify a brain-to-spinal pathway that contributes to morphine-induced mechanical hypersensitivity and analgesic tolerance in mice. Their findings connect MOR-expressing neurons in the lateral parabrachial nucleus with hypothalamic dynorphin neurons and KOR-expressing spinal GABAergic neurons, highlighting a circuit-level mechanism that may be tested in future opioid receptor signaling research.
-
Okadaic acid (A4540): PP1/PP2A Workflow Guide
2026-09-24
Okadaic acid (A4540) provides a way to probe phosphorylation-dependent signaling by inhibiting PP2A at lower concentrations and PP1 at higher concentrations. Use it in carefully controlled phosphatase and cell-response experiments; it is not a stand-alone apoptosis reagent or a substitute for a broad-spectrum phosphatase inhibitor.
-
Anti-RPS6 Antibody Workflows for PDAC Research
2026-09-24
Connect membrane-signaling perturbations to ribosomal-protein abundance with a practical Western blot, imaging, and immunoprecipitation strategy. The Anti-RPS6 (7B10) antibody recognizes total RPS6—not a specific phosphosite—so it is most informative when paired with phospho-specific and functional readouts.
-
Protease Inhibitor Cocktail for Tumor Assays
2026-09-23
Protect labile proteins during tumor-cell extraction without adding EDTA, which can interfere with divalent-cation-dependent downstream assays. This practical guide connects the cocktail to MCRS1–MHC-I research workflows, while distinguishing lysate preservation from measurements of intact-cell immune function.
-
SB 431542: ALK5 Inhibitor Workflow Guide
2026-09-23
Use SB 431542 to dissect TGF-β-driven Smad2 signaling, epithelial cell-state control, and selected cancer or immune phenotypes. This guide translates the corneal epithelial 6C culture paradigm into practical dose-finding, controls, readouts, and troubleshooting strategies.
-
Proteoform-Aware PDE5 Research with Vardenafil
2026-09-22
Vardenafil HCl Trihydrate offers translational researchers a potent, selective reference compound for connecting PDE5 inhibition with cGMP signaling, smooth muscle physiology, and proteoform-resolved drug discovery. This thought-leadership article explains how to move beyond a single enzymatic IC50 by integrating isoform profiling, tissue-based relaxation assays, erectile dysfunction models, and native mass spectrometry. It also examines why PDE6 off-target interactions and protein lipidation make native biological context essential for interpreting selectivity.